Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22955339 | 0.83 | NCF1 (0.41) | POLBALDH1A1GAAPKML3MBTL1 | |
| SCHEMBL18595930 | 0.82 | CYP1A2 (0.34) | ALDH1A1GAACYP1A2CYP2D6 | |
| SCHEMBL18745447 | 0.81 | POLB (0.35) | POLBALDH1A1GAAPKML3MBTL1 | |
| SCHEMBL15706251 | 0.78 | THRA (0.34) | — | |
| SCHEMBL21743370 | 0.77 | HRH3 (0.37) | POLBALDH1A1GAAPKML3MBTL1 | |
| SCHEMBL19050582 | 0.77 | POLB (0.33) | POLBALDH1A1GAAPKML3MBTL1 | |
| SCHEMBL20089204 | 0.75 | POLB (0.32) | POLBALDH1A1GAACYP1A2CYP2D6 | |
| SCHEMBL22878885 | 0.75 | CYP1A2 (0.32) | CYP1A2CYP2D6 | |
| SCHEMBL179555 | 0.74 | ALDH1A1 (0.41) | ALDH1A1GAACYP1A2CYP2D6 | |
| SCHEMBL23788712 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ADVANCION CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | NME4, NMBR, NMUR1 | POLB 491/4885ALDH1A1 1133/4885GAA 2672/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | POLB 325/4885ALDH1A1 482/4885GAA 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.